Predictmedix AI Launches Next-Generation Clinical-Trial AI Platform

2025-10-01 12:04:58

(MENAFN- Newsfile Corp) Adaptive "digital brain" designed to cut risk, cost and timelines in the $70-billion clinical-trials market ¹

Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, announced the launch of its Clinical-Trial AI Platform, an AI-driven solution intended to help pharmaceutical sponsors and contract research organizations (CROs) model, plan, and adapt clinical trials more efficiently.

A Digital Brain for Clinical Trials

Built on patented technology and the high-fidelity dataset generated by SmartHealth AI Stations, the platform is designed to function as a real-time digital support system for trial planning. It ingests and harmonizes diverse datasets-patients, protocols, sites, historical outcomes, and costs-and can update analyses as new data becomes available.

Key Features

Adaptive Simulation Engine - Runs "what-if" scenarios and refreshes projections as enrollment and site-performance information is received.

Patient-Site Optimization - Uses AI to recommend patient-site matching that may improve recruitment and reduce dropouts.

Cost & ROI Modeling - Proprietary algorithms estimate potential budget impact alongside predicted clinical outcomes.

Interactive Dashboards - Executive and audit views visualize risk, cost, and patient flow with dynamic heatmaps and Sankey plots.

Compliance-Integrated AI - Tracks data inputs and simulations to support audit and regulatory processes.

Market Context

Industry analysts estimate the global clinical-trials market could exceed $70 billion by 2027¹, creating demand for tools that help sponsors reduce trial failures, improve patient recruitment, and manage costs. Predictmedix's platform is intended to address these needs with scalable, real-time analytics.

"Clinical development urgently needs smarter tools," said Dr. Rahul Kushwah, COO of Predictmedix. "Our platform is designed to highlight potential clinical trial challenges early, enabling sponsors to make informed adjustments that can help save time and resources and, ultimately, support faster delivery of new therapies."

Distinctive Capabilities

The platform is built around real-time adaptive AI, with automation applied across data ingestion, simulation, and outcome modeling.

Continuous Intelligence: Projections adjust as enrollment numbers, site performance, or protocol variables change.

End-to-End Automation: From raw data to executive dashboards, workflows are automated to reduce manual reconciliation.

Multi-Trial Orchestration: A single environment can simulate multiple protocols and allocate resources across a development portfolio.

Cost-Outcome Integration: Financial modeling is embedded directly into clinical predictions for unified decision support.

Validated Data Streams: The system draws on more than 500,000 SmartHealth scans, which internal and third-party assessments have measured at approximately 95 % accuracy for vital-sign detection; actual results may vary.

Predictmedix is preparing to provide private demonstrations and explore paid pilot programs with pharmaceutical sponsors and CROs as opportunities emerge.

Detailed analysis of the company's direct comparables that are trading on CSE and/or TSXV can be found here : . Details of the company's recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: .

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Smarthealth AI stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter , Instagram or LinkedIn .

Contact
Dr. Rahul Kushwah, COO
...
(647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit

SOURCE: Predictmedix AI Inc.

MENAFN01102025004218003983ID1110133836

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.